

Rec'd PCT/PTO 21 SEP 2004

#6

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Susan L. Buis

Type or print name of person signing certification

Susan L. Buis

Signature

9-21-04

Date

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ryan Thomas Backer, et al.

)

Serial No.: 10/500,476

)

International

)

Filing Date: January 21, 2003

)

For: MELANOCORTIN RECEPTOR AGONISTS

)

Docket No.: X-15476

)

COMMUNICATION

Commissioner for Patents


P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

This application pertains to small molecule and thus doesn't require to disclose nucleotide and/or amino acid sequence.

Respectfully submitted,



 Soonhee Jang
 Attorney for Applicants
 Registration No. 44,802
 Phone: 317-651-3571

 Eli Lilly and Company
 Patent Division/SJ
 P.O. Box 6288
 Indianapolis, Indiana 46206-6288

Page 1 of 2



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY DOCKET NO
10/500,476	Ryan Thomas Backer	X-15476
INTERNATIONAL APPLICATION NO.		
PCT/US03/00033		
LA. FILING DATE	PRIORITY DATE	
01/21/2003		
CONFIRMATION NO. 9111		
371 FORMALITIES LETTER		
OC000000013730476		

25885
 ELI LILLY AND COMPANY
 PATENT DIVISION
 P.O. BOX 6286
 INDIANAPOLIS, IN 46206-6286

RECEIVED

SEP 14 2004

ELI LILLY & COMPANY, PATENT DEPT.

Date Mailed: 09/08/2004

DUE 11-8-2004

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
 CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c) and PCT Rule 5.2(a).
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e) and PCT Rule 13ter.1(a)(ii).
 - **APPLICANT MUST PROVIDE:**
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 305-4216
 - To Purchase Patentin Software, call (703) 306-2600
 - For Patentin Software Program Help, call (703) 308-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5).

*A copy of this notice **MUST** be returned with the response.*

BARBARA A CAMPBELL

Telephone: (703) 305-3631

Fax

Rec'd PCT/PTC 21 SEP 2004
Lilly

LRL LAW - PATENT DEPARTMENT

To: Barbara A. CampbellEli Lilly and Company
Lilly Corporate Center
Indianapolis, Indiana 46285
U.S.A.Company: USPTO
Fax: 703-746-6705
Phone: 703-305-3423
Date: September 21, 2004From: Soonhee Jang
Fax: 317-276-3861
Phone: 317-651-3571
Total Pages: 3

This facsimile message is intended only for the individual to whom it is addressed and may contain information that is privileged, confidential or exempt from disclosure under applicable law. If you have received this facsimile in error, please notify us immediately by telephone (collect), and return the original message to us at the above address via U.S. Postal Service.